Epidemiology and Genomics Research
CANCER EPIDEMIOLOGY MATTERS E-NEWS
MARCH 2017

Follow us on Twitter
March 2017 Features
Announcements
Contact Us
FOAsFunding
 Opportunity Announcements
 
PA-17-224  (Admin Supp)
Research Supplements to Promote Sharing Data in Cancer Epidemiology Studies
Applications Due: June 1, 2017
Expiration Date: June 2, 2017

PA-17-223 (Admin Supp)
Supplement Opportunity to Support Population-Based Research Studies of Rare Cancers
Applications Due: June 1, 2017
Expiration Date: June 2, 2017

Supplements for Validating the Use of Automated Sources of Residential Histories in Cancer Epidemiology Cohorts
Applications Due: June 1, 2017
Expiration Date: June 2, 2017

RFA-CA-017 (R01)
RFA-CA-018 (R21)
Research Answers to NCI's Provocative Questions 

Applications Due: June 28, 2017; October 30, 2017; June 28, 2018; October 30, 2018
Expiration Date: October 31, 2018 

RFA-CA-17-019 (R01) RFA-CA-17-021 (P01)
RFA-CA-17-022  (P50)
Revision Applications to NCI-Supported Awards to Include Research on the NCI's Provocative Questions
Applications Due: June 28, 2017; October 30, 2017; June 28, 2018; October 30, 2018
Expiration Date: October 31, 2018

PAR-17-151 (R01)
PAR-17-150  (R21)
Mechanisms of Disparities in Chronic Liver Diseases and Cancer  
Applications Due: May 22, 2017; April 4, 2018; April 4, 2019
Expiration Date: April 5, 2019
 
Notice of Intent to Publish a Funding Opportunity Announcement for New Epidemiology Cohorts in Heart, Lung, Blood, and Sleep Diseases and Disorders (U01)
 
Notice of Intent to Publish a Funding Opportunity Announcement for Continuation of Existing Grant Based Epidemiology Cohort Studies in Heart, Lung, Blood, and Sleep Diseases and Disorders (U01)
PolicyGrants Policy Announcements
Update and Clarification: NIH Continuous Submission Policy

NOT-OD-17-050
Reporting Preprints and Other Interim Research Products

NOT-OD-17-049
Interim Guidance on Salary Limitation for Grants and Cooperative Agreements

NOT-CA-17-042
NCI Will Support Training in Patient-Oriented Research Through K08 Awards and Increase K08 Salary and Research Support

NOT-OD-17-048
NIH Operates Under a Continuing Resolution

 
Comments due by April 16, 2017

Comments due by April 30, 2017
JobJob Opportunities
 


EventsUpcoming Webinars & Workshops
April 6, 2017
Bethesda, MD

Infectious Agents and Cancer Epidemiology Research Webinar Series
April 11, 2017

May 3-5, 2017
New Orleans, LA

May 4-5, 2017
Memphis, TN

May 16-17, 2017
Bethesda, MD

May 31-June 1, 2017
Rockville, MD

International Conference on Ambulatory Monitoring of Physical Activity and Movement
June 21-23, 2017
Bethesda, MD
BlogsBlog Posts
NCI Cancer Currents
AboutAbout EGRP
The Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS) funds research in human populations to understand the causes of cancer and related outcomes.

The Program fosters interdisciplinary collaborations, as well as the development and use of resources and technologies to advance cancer research and translation of this research, which serve as the basis for clinical and public health interventions.
ContactContact Us
email: nciepimatters@mail.nih.gov
website: epi.grants.cancer.gov
twitter: twitter.com/NCIEpi
AACR
The 2017 AACR Annual Meeting: 16 Sessions for Epidemiologists
AACR 2017 Annual Meeting 
The 108th Annual Meeting of the American Association for Cancer Research (AACR) will take place from April 1-5, 2017 in Washington, DC. To help those planning to attend make the most out of their time at this year's meeting, the Epidemiology and Genomics Research Program (EGRP) has assembled a list of selected sessions presented by National Cancer Institute (NCI) staff, grantees, and collaborators that highlight important resources and topics in cancer epidemiology and genomics, funding opportunities, and grantsmanship issues.   

For more epidemiology sessions during the conference, check out MEG at the Annual Meeting, a list compiled by AACR's Molecular Epidemiology Interest Group, and the Epidemiology Track in the AACR Annual Meeting Online Itinerary Planner.

Sunday, April 2:
Monday, April 3: Tuesday, April 4: Wednesday, April 5: If you are attending AACR this year, don't forget to add these sessions to your personal meeting itinerary before you go. Visit the NCI website to sign up for emails on NCI participation at AACR and other conferences. 
PQ 
NCI Publishes New Provocative Questions Initiative Funding Opportunity Announcements 
The NCI's Provocative Questions (PQ) Initiative is intended to stimulate specific areas of cancer research that are understudied, neglected, paradoxical, and/or have been difficult to address in the past. 
 
NCI has identified 12 PQs in the Funding Opportunity Announcements (FOAs) published in March 2017. Investigators are encouraged to submit a letter of intent 30 days prior to the application due date to determine whether their proposed research idea is responsive to one of the 12 PQs.  The 2017 application receipt dates are June 28 and October 30. 

The following PQs may be of particular interest to population science researchers:
  • PQ-1: What molecular mechanisms influence disease penetrance in individuals who inherit a cancer susceptibility gene?
  • PQ-2: How do variations in immune function caused by comorbidities or observed among different populations affect response to cancer therapy?
  • PQ-3: Do genetic interactions between germline variations and somatic mutations contribute to differences in tumor evolution or response to therapy?
  • PQ-6: How do circadian processes affect tumor development, progression, and response to therapy?
  • PQ-10: How do microbiota affect the response to cancer therapies?
  • PQ-11: Through what mechanisms do diet and nutritional interventions affect the response to cancer treatment?
  • PQ-12: What are the molecular and/or cellular mechanisms that underlie the development of cancer therapy-induced severe adverse sequelae?
The other questions can be viewed on NCI's PQ Initiative website
 
There are also four additional FOAs intended for revision applications (formerly referred to as competing supplements) to add PQ-relevant research to eligible NIH and/or NCI-supported parent awards for R01, U01, P01, and P50 awards.

To be considered eligible to respond to one of the PQ FOAs for revision applications, investigators must have at least two years remaining in their original award period or no-cost extension. No more than two years of support can be requested and the budget cap is $150,000 direct costs per year.

The revision applications will be reviewed by the same Special Emphasis Panels (SEPs) that review the Provocative Questions initiative R01 and R21 applications.

Learn more about the PQ FOAs through the NIH Guide for Grants and Contracts
For questions or more information about the PQ Initiative, visit the Initiative's website or e-mail NCIProvocativeQuestions@mail.nih.gov.

Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute | 9609 Medical Center Drive | 4 East, MSC 9763 | Bethesda | MD 20892


Contact Us |Privacy Policy  | Accessibility | FOIA

 U.S. Department of Health and Human Services 
 National Institutes of Health National Cancer Institute | USA.gov